CD40-CD40 ligand (CD40L) signaling complex (CD40-CD40L)

The CD40–CD40L co-stimulatory interaction is a critical immune checkpoint axis comprising the CD40 receptor (TNFRSF5) and its ligand, CD40L (CD154 or TNFSF5) (UniProt P25942, P29965). This interaction is essential for the activation and maturation of antigen-presenting cells (APCs), such as dendritic cells and B cells, by activated T helper cells (PMID: 19172135). Upon binding, CD40 signaling triggers the NF-κB and MAPK pathways, leading to B-cell proliferation, immunoglobulin class switching, and the licensing of dendritic cells to prime cytotoxic T-cell responses (PMID: 31439475). In oncology, CD40 agonists are utilized to stimulate anti-tumor immunity by enhancing APC function, whereas in autoimmune diseases and transplantation, CD40-CD40L antagonists are employed to suppress pathological immune activation (PMID: 30617125). Historically, CD40L-targeting therapies faced safety hurdles due to thromboembolic risks linked to CD40L expression on platelets, prompting the development of next-generation CD40-specific antibodies and Fc-modified CD40L blockers (PMID: 10811864).

Other names

CD40-CD154 interactionTNFRSF5-TNFSF5 axisCD40-CD40L co-stimulatory pathwayCD40-CD40L axis

Therapeutic strategies involve either CD40 agonism to enhance antigen-presenting cell activation for cancer immunotherapy or CD40-CD40L blockade to inhibit co-stimulatory signaling in autoimmune and transplant conditions.